REG - Oxford Biomedica PLC - Full year Trading Update and Notice of Results

Oxford BioMedicaAnnouncement

Tue 07:05

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260224:nRSX1598Ua&default-theme=true

RNS Number : 1598U  Oxford Biomedica PLC  24 February 2026

 

Full year Trading Update and Notice of Results

Revenues at the upper end of guidance and pivot to EBITDA profitability -
expectations for 2026 unchanged and guidance reiterated

 

 

-       Revenues expected to increase c.30% as OXB continues to execute
its strategy, FY 2025 revenues expected to be £166-169 million (£168 - 171
million CC(1)), at the upper end of guidance of £160-170 million (CC) (FY
2024: £128.8 million)

 

-       FY 2025 Operating EBITDA(2) profitability expected to be
mid-to-high single-digit £ million (CC) including a larger than expected
non-recurring gain from the Durham, NC acquisition; excluding the impact of
the acquisition, underlying Operating EBITDA profit expected to be low
single-digit £ million  (CC) for FY 2025 (FY 2024: £(15.3) million loss) in
line with guidance

 

-       FY 2025 contracted value of client orders(3) increased 20% to
£224 million (FY 2024: £186 million); reflecting increased demand from both
existing and new clients

 

Oxford, UK - 24 February 2026: OXB (LSE: OXB), a global quality and
innovation-led cell and gene therapy CDMO, provides a trading update for the
full year ended 31 December 2025.

 

Dr. Frank Mathias, Chief Executive Officer of OXB, commented: "2025 has been
a milestone year for OXB, in which we continued to successfully execute our
pure-play CDMO strategy and expect to deliver an outstanding full-year
performance with continued strong revenue growth and EBITDA-level
profitability.

"Expected FY 2025 revenues represent a nearly 90% growth since FY 2023,
further demonstrating the scale and momentum we have built over the past two
years. These results reflect sustained demand for our viral vector services,
and improved operational efficiency throughout our global network."

 

Strong 2025 performance expected to deliver EBITDA profitability

For the year ended 31 December 2025, OXB (the "Company") expects to report
revenues of £166-169 million (£168 - 171 million CC), at the upper end of
guidance of £160 - £170 million (CC). This performance represents an
increase of c.30% over FY 2024 revenues of £128.8 million and an almost 90%
revenue growth since FY 2023, reflecting the strong execution of the Company's
pure‑play CDMO strategy and sustained demand as client programmes progress.

 

For FY 2025 the Company expects to report mid-to-high single-digit £ million
Operating EBITDA profitability (CC), which includes a larger than expected
non-recurring gain associated with the acquisition
(https://www.londonstockexchange.com/news-article/OXB/acquisition-of-us-viral-vector-facility/17266066)
of a viral vector manufacturing facility in Durham, North Carolina (NC) from
National Resilience, Inc. in October 2025. On an underlying basis, excluding
the impact of this acquisition and the associated costs, Operating EBITDA is
expected to be in line with guidance of low single-digit £ million
profitability (CC), driven by increased revenue growth, operational efficiency
and disciplined cost control.

 

OXB closed the year with a strong balance sheet, including a gross cash
position of £96.9 million and a net cash position of £55.4 million. The
balance sheet was strengthened by a c.£60 million equity raise
(https://www.londonstockexchange.com/news-article/OXB/proposed-placing-of-new-ordinary-shares/17185418)
in August 2025 and entry into a new four-year loan facility
(https://www.londonstockexchange.com/news-article/OXB/oxb-secures-new-loan-facility-with-oaktree/17162863)
of up to $125 million with Oaktree, of which $60 million has been drawn to
date, of which $50 million was used to repay the existing loan facility.
Together, these provide additional liquidity and support for planned capacity
expansion to meet growing client demand and the pursuit of OXB's medium-term
ambitions.

 

Commercial momentum supporting growth in 2026 and beyond

Reflecting increasing demand for OXB's services, the contracted value of
client orders reached £224 million for the year ended 31 December 2025, an
increase of 20% compared to £186 million for the year ended 31 December 2024.
Revenue backlog(4) stood at approximately £204 million as at 31 December
2025 compared to approximately £150 million as at 31 December 2024.

 

As a result of this commercial momentum, the Company expects to continue to
deliver above-market revenue growth, and an expansion of EBITDA margins
following positive Operating EBITDA in 2025. The Company therefore reiterates
its short- and medium-term financial guidance.

 

FY 2026 revenues are expected to be between £220-240 million (CC). The
Company expects 25-30% year-on-year revenue growth in 2027 and 2028, ahead of
the broader market. Operating EBITDA margin is expected to exceed 10% in FY
2026 and be at least 20% for FY 2027, with long-term potential to approach
c.30% (within a five-to-six year time period) as expanded capacity is
utilised.

 

Notice of Preliminary Results

OXB will report its preliminary results for the twelve months ended 31
December 2025 on 26 March 2026. OXB's management team, led by Dr. Frank
Mathias, CEO, Dr. Lucinda Crabtree, CFO and Dr. Sebastien Ribault, CBO will
host a virtual analyst briefing at 13:00 GMT / 08:00 ET. To register, please
contact oxb@icrhealthcare.com (mailto:oxb@icrhealthcare.com) .

 

(1) CC refers to constant currency, the equivalent values based on the prior
year exchange rates.

(2) Operating EBITDA (Earnings Before Interest, Tax, Depreciation,
Amortisation, revaluation of investments and assets at fair value through
profit and loss, and share based payments) is a non-GAAP measure often used as
a surrogate for operational cash flow as it excludes from operating profit or
loss all non-cash items, including the charge for share based payments.

 

(3) Contracted value of client orders represents the gross value of customer
orders for which the customer has signed a financial commitment, whereby any
changes to agreed values will be subject to either change orders, cancellation
fees or the triggering of optional/contingent contractual clauses.

 

(4) Revenue backlog represents the ordered gross value of CDMO revenues
available to earn. The value of customer orders included in revenue backlog
only includes the value of work for which the customer has signed a financial
commitment for OXB to undertake, whereby any changes to agreed values will be
subject to change orders, cancellation fees or the triggering of
optional/contingent contractual clauses.

 

 

 

-Ends-

 

 

 

Enquiries:

 

OXB:

Sophia Bolhassan, Head of Investor Relations - T: +44 (0) 1865 509 737 / E:
ir@oxb.com (mailto:ir@oxb.com)

ICR Healthcare:

T: +44 (0)20 3709 5700 / E: oxb@icrhealthcare.com

Mary-Jane Elliott / Angela Gray / Davide Salvi

 

 

About OXB

 

OXB (LSE: OXB) is a global quality and innovation-led contract development and
manufacturing organisation (CDMO) in cell and gene therapy with a mission to
enable its clients to deliver life changing therapies to patients around the
world.

 

One of the original pioneers in cell and gene therapy, OXB has 30 years of
experience in viral vectors; the driving force behind the majority of cell and
gene therapies. OXB collaborates with some of the world's most innovative
pharmaceutical and biotechnology companies, providing viral vector development
and manufacturing expertise in lentivirus, adeno-associated virus (AAV),
adenovirus and other viral vector types. OXB's world-class capabilities range
from early-stage development to commercialisation. These capabilities are
supported by robust quality-assurance systems, analytical methods and depth of
regulatory expertise.

 

OXB offers a vast number of technologies for viral vector manufacturing,
including a 4th generation lentiviral vector system (the TetraVecta™
system), a dual-plasmid system for AAV production, suspension and perfusion
process using process enhancers and stable producer and packaging cell lines.

 

OXB, a FTSE 250 and FTSE4Good constituent, is headquartered in Oxford, UK. It
has development and manufacturing facilities across Oxfordshire, UK, Lyon and
Strasbourg, France, Bedford MA, and Durham NC, US. Learn more at www.oxb.com
(http://www.oxb.com) and follow us on LinkedIn
(https://www.linkedin.com/company/oxford-biomedica) and YouTube.
(https://www.youtube.com/oxfordbiomedica)

 

APPENDIX: RULE 28 OF THE TAKEOVER CODE

 

FY25 Profit Estimate

The following statements included in this announcement constitute an ordinary
course profit forecast for the purposes of Rule 28.1(a) and Note 2(b) on Rule
28.1 of the Takeover Code (the "FY25 Profit Estimate"):

"FY 2025 Operating EBITDA(2) profitability expected to be mid-to-high
single-digit £ million (CC) including a larger than expected non-recurring
gain from the Durham, NC acquisition; excluding the impact of the acquisition,
underlying Operating EBITDA profit expected to be low single-digit £ million
(CC) for FY 2025 (FY 2024: £(15.3) million loss) in line with guidance."

"For FY 2025 the Company expects to report mid-to-high single-digit £ million
Operating EBITDA profitability (CC), which includes a larger than expected
non-recurring gain associated with the acquisition of a viral vector
manufacturing facility in Durham, North Carolina (NC) from National
Resilience, Inc. in October 2025. On an underlying basis, excluding the impact
of this acquisition and the associated costs, Operating EBITDA is expected to
be in line with guidance of low single-digit £ million profitability (CC),
driven by increased revenue growth, operational efficiency and disciplined
cost control."

FY26 Profit Forecast

In addition, the following statements included in this announcement constitute
an ordinary course profit forecast for the purposes of Rule 28.1(a) and Note
2(b) on Rule 28.1 of the Code (the "FY26 Profit Forecast"):

"FY 2026 revenues are expected to be between £220-240 million (CC). The
Company expects 25-30% year-on-year revenue growth in 2027 and 2028, ahead of
the broader market. Operating EBITDA margin is expected to exceed 10% in FY
2026 and be at least 20% for FY 2027, with long-term potential to approach
c.30% (within a five-to-six year time period) as expanded capacity is
utilised."

"Expectations for 2026 unchanged and guidance reiterated"

"The Company therefore reiterates its short- and medium-term financial
guidance."

FY27 Profit Forecast

In addition, the following statements included in this announcement
constitutes a profit forecast for a financial period ending more than 15
months from the date in which it is published for the purposes of Rule 28.2(a)
of the Code (the "FY27 Profit Forecast"):

"FY 2026 revenues are expected to be between £220-240 million (CC). The
Company expects 25-30% year-on-year revenue growth in 2027 and 2028, ahead of
the broader market. Operating EBITDA margin is expected to exceed 10% in FY
2026 and be at least 20% for FY 2027, with long-term potential to approach
c.30% (within a five-to-six year time period) as expanded capacity is
utilised."

"Expectations for 2026 unchanged and guidance reiterated"

"The Company therefore reiterates its short- and medium-term financial
guidance."

Directors' confirmation

Pursuant to Note 2(a) to Rule 28.1 and Rule 28.2(a) of the Code, the Panel
granted a dispensation from the Code requirement for the Company's reporting
accountants and financial advisers to prepare reports in relation to the FY25
Profit Estimate, FY26 Profit Forecast, and FY27 Profit Forecast.

In accordance with Rule 28.1(c)(i) of the Code, the OXB Directors confirm that
the FY25 Profit Estimate, FY26 Profit Forecast, and FY27 Profit Forecast
remain valid as at the date of this announcement and each has been properly
compiled on the basis of the assumptions stated below, and that the basis of
accounting used is consistent with OXB's accounting policies.

Basis of preparation

The FY25 Profit Estimate is based on OXB's current internal unaudited
consolidated accounts for the year ended 31 December 2025. The basis of the
accounting policies used in the FY25 Profit Estimate is consistent with the
existing accounting policies of the Company. These policies are consistent
with those applied in the preparation of OXB's annual results for the year
ended 31 December 2024.

The FY26 and FY27 Profit Forecasts are based on internal OXB forecasts on a
constant currency basis. The basis of the accounting policies used in the FY26
Forecast and FY27 Profit Forecast is consistent with the existing accounting
policies of the Company.

Assumptions

The FY25 Profit Estimate is not based on any assumptions.

The FY26 Profit Forecast and the FY27 Profit Forecast are based on the
following assumptions:

Factors outside the influence or control of the OXB Directors

·        There will be no material changes to existing prevailing
macroeconomic or political conditions in the markets and regions in which the
Company operates.

·        There will be no material changes to the general market
conditions or the behaviour of competitors in the markets and regions in which
the Company operates.

·        There will be no material adverse change to the Company's
commercial relationships or customer demand.

·        Interest rates, inflation, foreign exchange rates and tax
rates in the markets and regions in which the Company operates will remain
materially unchanged from prevailing levels.

·        There will be no material adverse events that have a
significant impact on the Company's financial performance, including business
disruptions affecting the Company or its key customers.

·        There will be no material changes in legislation, regulatory
requirements or accounting policies that materially impact the Company's
operations or reported results.

·        There will be no material litigation in relation to any of
the Company's operations.

Factors within the influence and control of the OXB Directors

·        There will be no material change to the present management of
the Company.

·        There will be no material change in the operational strategy
of the Company.

·        There will be no material adverse change in the Company's
ability to maintain customer and partner relationships.

·        There will be no material acquisitions or disposals.

·        There will be no material strategic investments over and
above those currently planned.

·        There will be no material change in the dividend or capital
policies of the Company.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCKZGZZVDLGVZG



            Copyright 2019 Regulatory News Service, all rights reserved